GlassScriptPhysician profile
Jinok Chung
NPI 1841385325
$2,375.89
in general payments reported to CMS, 2019-2025
13 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $14.03 · 2021: $73.21 · 2022: $28.96 · 2023: $208 · 2024: $155 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,085 · Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,084.94 |
| Food and Beverage | $998.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,477.20 | 2025 | Micra |
| Boston Scientific Corporation | $197.74 | 2023-2025 | Cds Broad Portfolio Offering |
| E.R. Squibb & Sons, L.L.C. | $158.87 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $152.91 | 2019-2023 | Mitraclip |
| Pfizer INC. | $117.92 | 2020-2024 | |
| Irhythm Technologies, INC. | $73.03 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.77 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $46.99 | 2023-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $22.12 | 2024 | |
| Amarin Pharma, INC. | $18.76 | 2021 | |
| Fisher & Paykel Healthcare INC | $18.56 | 2024 | Fisher & Paykel Healthcare |
| Astrazeneca Pharmaceuticals LP | $13.20 | 2023 | Andexxa |
| Edwards Lifesciences Corporation | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinok Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.